Amneal Pharmaceuticals Inc. (AMRX)
Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and AtriCure (ATRC) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
3 Reasons Growth Investors Will Love Amneal (AMRX)
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect?
The mean of analysts' price targets for Amneal (AMRX) points to a 54.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is Why Growth Investors Should Buy Amneal (AMRX) Now
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2025 Earnings Call May 2, 2025 8:30 AM ET Company Participants Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Officer Chintu Patel - Co-Founder and Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities Chris Schott - JPMorgan Operator Good morning and welcome to the Amneal Pharmaceuticals First Quarter 2025 Earnings Call. I'd now like to turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago.
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued
Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price appreciation. The company reported strong 2024 financials, with revenues up 17% year-on-year, and forecasts continued growth in 2025, driven by diverse product segments. Amneal is reducing debt effectively, targeting a net debt to EBITDA ratio of 3.6-3.7 in 2025, enhancing financial stability and investor confidence.
